CN101355949A - 三嗪衍生物与胰岛素分泌促进剂的组合 - Google Patents

三嗪衍生物与胰岛素分泌促进剂的组合 Download PDF

Info

Publication number
CN101355949A
CN101355949A CNA2006800507984A CN200680050798A CN101355949A CN 101355949 A CN101355949 A CN 101355949A CN A2006800507984 A CNA2006800507984 A CN A2006800507984A CN 200680050798 A CN200680050798 A CN 200680050798A CN 101355949 A CN101355949 A CN 101355949A
Authority
CN
China
Prior art keywords
alkyl
alkoxyl
amino
optional
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800507984A
Other languages
English (en)
Chinese (zh)
Inventor
G·穆瓦内
D·克拉沃
D·梅桑若
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Polk Zale Corporation
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN101355949A publication Critical patent/CN101355949A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2006800507984A 2006-01-13 2006-12-18 三嗪衍生物与胰岛素分泌促进剂的组合 Pending CN101355949A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0600342A FR2896157B1 (fr) 2006-01-13 2006-01-13 Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
FR06/00342 2006-01-13

Publications (1)

Publication Number Publication Date
CN101355949A true CN101355949A (zh) 2009-01-28

Family

ID=36648317

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800507984A Pending CN101355949A (zh) 2006-01-13 2006-12-18 三嗪衍生物与胰岛素分泌促进剂的组合

Country Status (21)

Country Link
US (1) US8227465B2 (cg-RX-API-DMAC10.html)
EP (1) EP1971339B1 (cg-RX-API-DMAC10.html)
JP (1) JP5702911B2 (cg-RX-API-DMAC10.html)
KR (1) KR20080091366A (cg-RX-API-DMAC10.html)
CN (1) CN101355949A (cg-RX-API-DMAC10.html)
AR (1) AR059030A1 (cg-RX-API-DMAC10.html)
AT (1) ATE540682T1 (cg-RX-API-DMAC10.html)
AU (1) AU2006334731B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0620923A2 (cg-RX-API-DMAC10.html)
CA (1) CA2636837C (cg-RX-API-DMAC10.html)
CY (1) CY1112674T1 (cg-RX-API-DMAC10.html)
DK (1) DK1971339T3 (cg-RX-API-DMAC10.html)
EA (1) EA016649B1 (cg-RX-API-DMAC10.html)
ES (1) ES2378469T3 (cg-RX-API-DMAC10.html)
FR (1) FR2896157B1 (cg-RX-API-DMAC10.html)
IL (1) IL192596A (cg-RX-API-DMAC10.html)
PL (1) PL1971339T3 (cg-RX-API-DMAC10.html)
PT (1) PT1971339E (cg-RX-API-DMAC10.html)
SI (1) SI1971339T1 (cg-RX-API-DMAC10.html)
WO (1) WO2007079914A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200806938B (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2530223T3 (es) 2008-12-12 2015-02-27 Poxel S.A.S. Combinación de insulina con derivados de triazina y su uso para tratar la diabetes
FR2948028B1 (fr) * 2009-07-17 2011-12-02 Merck Sante Sas Association d'un inhibiteur de l'echangeur sodium-proton et d'un derive amine de dihydro-1,3,5-triazine
RU2550798C2 (ru) * 2011-05-12 2015-05-10 Василий Иосифович Зоря Способ стимуляции секреции инсулина
FR2987268B1 (fr) 2012-02-28 2014-07-11 Ammtek Formulations liquides de sulfamides hypoglycemiants
TWI748945B (zh) * 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
EP3691650A1 (en) 2017-10-02 2020-08-12 Poxel Methods of treating heart failure with preserved ejection fraction
MY203360A (en) 2018-06-06 2024-06-26 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
CA3103324A1 (en) * 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
USD945167S1 (en) 2018-10-31 2022-03-08 Kimberly-Clark Worldwide, Inc. Paper sheet
KR20220113942A (ko) * 2019-12-13 2022-08-17 스미토모 파마 가부시키가이샤 제조성 및 용출성이 우수한 소형 정제
US12280125B2 (en) 2022-09-09 2025-04-22 Imam Abdulrahman Bin Faisal University Method for delivering insulin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
FR2781152B1 (fr) 1998-07-20 2001-07-06 Permatec Tech Ag Utilisation d'un polymere de type acrylique en tant qu'agent de desagregation
SI1133312T1 (sl) * 1999-06-21 2008-02-29 Lilly Co Eli Uporaba tiazolidindionov v kombinaciji z glukagonu podobnim peptidom-1 in njegovimi agonisti za zdravljenje sladkorne bolezni, neodvisne od inzulina
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
ATE385421T1 (de) * 2000-01-21 2008-02-15 Novartis Pharma Gmbh Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
ITFI20010126A1 (it) 2001-07-09 2003-01-09 Molteni & C Composizioni farmaceutiche per uso orale,contenenti,in combinazione,metformina e gliclazide
ATE361065T1 (de) * 2002-01-25 2007-05-15 Silanes Sa De Cv Lab Pharmazeutische zusammensetzung zur kontrolle des blutzuckers bei patienten mit typ 2 diabetes
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
FR2853650B1 (fr) * 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
AU2004267955A1 (en) * 2003-09-02 2005-03-10 Prosidion Ltd. Combination therapy for glycaemic control

Also Published As

Publication number Publication date
BRPI0620923A2 (pt) 2011-11-29
CY1112674T1 (el) 2016-02-10
CA2636837C (en) 2013-12-10
US20100233255A1 (en) 2010-09-16
SI1971339T1 (sl) 2012-07-31
PL1971339T3 (pl) 2012-04-30
FR2896157A1 (fr) 2007-07-20
ATE540682T1 (de) 2012-01-15
IL192596A0 (en) 2009-09-22
EA200801665A1 (ru) 2008-12-30
AU2006334731B2 (en) 2012-06-21
DK1971339T3 (da) 2012-02-20
JP2009523139A (ja) 2009-06-18
IL192596A (en) 2015-07-30
US8227465B2 (en) 2012-07-24
ES2378469T3 (es) 2012-04-12
WO2007079914A2 (en) 2007-07-19
EP1971339A2 (en) 2008-09-24
PT1971339E (pt) 2012-02-20
AU2006334731A1 (en) 2007-07-19
AR059030A1 (es) 2008-03-12
EP1971339B1 (en) 2012-01-11
JP5702911B2 (ja) 2015-04-15
ZA200806938B (en) 2010-02-24
WO2007079914A3 (en) 2007-09-07
CA2636837A1 (en) 2007-07-19
KR20080091366A (ko) 2008-10-10
EA016649B1 (ru) 2012-06-29
FR2896157B1 (fr) 2008-09-12

Similar Documents

Publication Publication Date Title
JP2009543767A (ja) フリバンセリンとカフェインとを含む組成物、その調製方法及び薬剤としての使用
JP2022504943A (ja) アミノピリミジン誘導体又はその塩を含む経口投与用医薬組成物
EP2945618B1 (en) Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders
EP3937908A1 (en) Formulations of a compound and uses thereof
CN101466365A (zh) 增强认知功能的方法
MX2012013617A (es) Uso de metformina en combinacion con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa.
JP2019501162A (ja) 慢性咳の処置のためのオルブピタント
TWI327468B (en) Pharmaceutical composition
EP1732559B1 (en) Methods of treatment using eszopiclone
CN101355933A (zh) 三嗪衍生物与胰岛素增敏剂的组合
US8227465B2 (en) Combination of triazine derivatives and insulin secretion stimulators
CN101898962B (zh) 大黄酸晶b型固体物质及制备方法与用途
AU2020389425A1 (en) Oral pharmaceutical composition comprising carbamate compound and preparation method therefor
US11236041B2 (en) Type-G crystal form of fenolamine, preparation method, composition and use thereof
TWI882128B (zh) 紫質症之預防或治療劑
CN101355935A (zh) 用于治疗糖尿病的三嗪衍生物与hmg-coa还原酶抑制剂的组合
US20250361243A1 (en) Compounds and Pharmaceutical Compositions Useful for Managing Sickle Cell Disease and Conditions Related Thereto
HK1128405A (en) Combination of triazine derivatives and insulin secretion stimulators
MX2008008894A (en) Combination of triazine derivatives and insulin secretion stimulators
HK1128232A (en) Combination of triazine derivatives and insulin sensitisers
HK1128231A (en) Combination of triazine derivatives and hmg-coa reductase inhibitors for the treatment of diabetes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1128405

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: BOCSILE CO.,LTD.

Free format text: FORMER OWNER: MERCK PATENT GMBH

Effective date: 20091106

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20091106

Address after: lyon

Applicant after: Polk Zale Corporation

Address before: Darmstadt

Applicant before: Merck Patent GmbH

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20090128

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1128405

Country of ref document: HK